While next-generation technologies have revolutionized the way genomes are sequenced, this technology possesses a fundamental weakness - the inability to easily target specific regions of a genome. To address this inefficiency in the workflow, a variety of methodologies for performing DNA target enrichment are being developed and commercialized. All methods have a particular "sweet spot" for performance: some are more appropriate for smaller studies, where only a few samples are being examined, while others have the ability to scale and use automation for studies ranging from low to ultra-high throughput. Costs, in terms of equipment and consumables, can also vary, depending on the technology used.
You are invited to join the discussion of strategies for DNA target enrichment with our panel of distinguished thought leaders in a live video webinar. During the broadcast, the presenters will:
- Provide a general introduction to the target enrichment methods they use
- Discuss how these technologies can be applied to the next-generation sequencing workflow
- Share data from studies that have benefited from their approach
- Answer your questions live!
Daniel Turner, Ph.D.
Wellcome Trust Sanger Institute
After gaining a degree in biochemistry from the University of Oxford in the United Kingdom, Dr. Turner went on to study for a Ph.D. at the University of Manchester, before moving to Francis Barany's lab at Cornell University Medical College as a postdoctoral research associate. His focus there was on developing and applying novel methods of single nucleotide polymorphism detection. Dr. Turner returned to the UK to take a postdoctoral position with Matthew Hurles at the Sanger Institute, where he performed research into genomic disorders, with an emphasis on assay development. His current role is as head of sequencing technology development at the Sanger Institute where he leads a research team that exploits a variety of presequencing technologies to develop novel “front end” applications for next-generation DNA sequencers. Dr. Turner also manages the institute's next-generation targeted resequencing pipeline.
Kelly Frazer, Ph.D.
Scripps Genomic Medicine
San Diego, CA
Dr. Frazer undertook her undergraduate and graduate training at the University of California, first at the Santa Cruz campus and then in San Francisco. She completed postdoctoral training at the Lawrence Berkeley National Laboratory, where she later became a staff scientist. Prior to joining the Scripps Research Institute in 2007, Dr. Frazer was vice president of genomics at Perlegen Sciences, where she played a key role in the HapMap Phase II project. Dr. Frazer is currently Professor of Translational Genomics at Scripps Research Institute and the Director of Genomic Biology in the Scripps Genomic Medicine Program. Her current research is focused on functionally characterizing human DNA variants underlying disease identified through whole genome association studies.
She has significant expertise with Next Generation sequencing technologies and advanced sample preparation methods.
Moderator: Sean Sanders, Ph.D.
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.